Results from UK study of the CST-Assistant show clinical relevance, cost-benefit and product-market fit

Copenhagen, Denmark, 3 September 2024– Brain+ A/S (Nasdaq First North: BRAINP)

A UK usability study of the CST-Assistant has been conducted in partnership with two local Age UK sites. Both sites have used the product to support the delivery of a full CST (Cognitive Stimulation Therapy) program to a group of people with dementia.

The results from the study confirm the clinical relevance and cost-benefit of the CST-Assistant. Also feedback from CST therapists and people with dementia, who participated in the study, was positive, demonstrating early product-market fit of the solution in a UK dementia management context. The results constitute important user and data evidence prior to release of the CST-Assistant into the attractive UK market by end September.

• Data from the Age UK study confirm that use of the CST-Assistant saves 50% of CST preparation time
• Participating CST therapists were satisfied with the CST-Assistant, confirming it makes planning of therapy significantly less difficult and that its content supports different cognitive and physical abilities as well as therapeutic needs of people with dementia
• The CST-Assistant was reported to provide for engaging and appropriately challenging CST sessions, making them fun and interactive for all participants
• The Age UK study data is early confirmation of product-market fit for the CST-Assistant in the UK

Brain+ A/S (“Brain+” or “the Company”) informs of supportive final results from a first UK usability study of the CST-Assistant, which has been conducted in partnership with two local Age UK sites in Trafford and in Tameside. The study was initiated in mid-March 2024, and both sites have delivered a full 14 sessions Cognitive Stimulation Therapy (CST) program to a group of people with dementia, using the CST-Assistant.

 

Age UK is the largest charity organization for seniors in the UK and a significant provider of CST to people with dementia. Data and user feedback from the study confirm that the CST-Assistant is clinically relevant, fits well with the UK workflow and provides cost-benefits in the delivery of CST.

 

Vikki-Rose Hawkins, Dementia Lead, Age UK Tameside, stated after the study:

 “I have been using the CST-Assistant with the group over the last few weeks. The app is easy to navigate and gives you ideas of what activities you can do. It makes planning the sessions so much easier. You have a choice of few activities, 3 of which you can choose as the main activities for each session, and I like to let the group choose on the day.”

 

Results from the study confirms that the CST-Assistant can save 50% of preparation time for CST therapists in connection with the delivery of a full therapy program. CST therapists in the study also reported that use of the CST-Assistant made planning of therapy significantly less difficult compared to not using the product, thus confirming the cost-benefits of the product to facilitate better CST offerings.

 

Users expressed satisfaction with all the content in the CST-Assistant, confirming its suitability for people with dementia spanning different cognitive and physical abilities and needs. This was further confirmed by people with dementia, who participated in the study, as they expressed satisfaction with the technology across all sessions. The CST-Assistant was reported to be fun and interactive for all study participants providing engaging and appropriately challenging activities.

 

Lucy Chidlow, Memory Loss Advisor, Age UK Trafford commented on the study:

“Age UK Trafford have collaborated with Brain+ for the past six months. The CST provided by Brain+ is an online system, that can be altered by the facilitator to suit the group, resources and environment. This method has suited our service users who have a diagnosis of Mild Cognitive Impairment (MCI) or have a recent Dementia diagnosis. A theme is set for each session, for example, orientation, using money or nostalgia towards childhood and the participants complete mental and physical exercises as well as a main activity.  As one participant said ‘I have really enjoyed today, but I have worked on my emotions, mental and physical health too.'”

 

The UK study results provide early evidence of the product-market-fit for the CST-Assistant in the UK, showing that the product fits well into the UK dementia care pathway and is considered valuable by both CST therapists and people with dementia receiving CST. The study results thus represent another important Market Access milestone leading up to the planned release of the product into the attractive UK market by end September and first UK sales before the end of 2024.

 

Brain+ invites to an Investor Webinar: Half-year 2024 report & meet new CCO

Time: Tuesday, 3 September 2024. 16:00 CEST

 

To get a more detailed insights into progress and plans join us tomorrow for our investor webinar, where you will also meet and be able to ask questions to our new Chief Commercial Officer, located in the UK, Devika Rani Woods.

 

Sign-up & pre-submit questions here.

 

Contact Information

CEO and Co-founder: Kim Baden-Kristensen, + 45 31 39 33 17 (SMS), [email protected]

 

Brain+ mission: Become the preferred provider of certified health tech solutions for better dementia management, servicing one million people affected by dementia by 2030.